Document 0384
 DOCN  M9460384
 TI    Response to inhibition of angiotensin-converting enzyme in human
       immunodeficiency virus-associated nephropathy: a case report.
 DT    9404
 AU    Burns GC; Matute R; Onyema D; Davis I; Toth I; Department of Medicine,
       St Vincent's Hospital and Medical Center; of New York, NY.
 SO    Am J Kidney Dis. 1994 Mar;23(3):441-3. Unique Identifier : AIDSLINE
       MED/94175065
 AB    The most common chronic nephropathy seen with human immunodeficiency
       virus (HIV) infection is characterized by heavy proteinuria and rapid
       deterioration of renal function. We here report the findings in an
       HIV-seropositive patient with nephrotic-range proteinuria and
       biopsy-proven HIV-associated nephropathy treated with the
       angiotensin-converting enzyme (ACE) inhibitor, fosinopril. During
       treatment periods, the patient demonstrated a significant decrement in
       24-hour urinary protein excretion without change in renal function. The
       patient acted as her own control. After discontinuation of the drug, the
       24-hour protein excretion deteriorated to pretreatment levels. ACE
       inhibition has been reported to decrease proteinuria and to have a
       beneficial influence on the progression of renal failure in diabetic and
       nondiabetic renal disease. To date, there is no known therapy for
       HIV-associated nephropathy. Our preliminary results in this patient
       suggest the need for long-term studies to assess whether this form of
       therapy can improve proteinuria over longer periods and, at the same
       time, ameliorate the progressive form of nephropathy seen in selected
       HIV-seropositive patients.
 DE    Adult  AIDS-Associated Nephropathy/*DRUG THERAPY  Case Report  Female
       Fosinopril/*THERAPEUTIC USE  Human  Proteinuria/DRUG THERAPY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).